PharmX Technologies (ASX:PHX) Moat Score: 0/10 (As of Jul. 01, 2026)


ASX:PHX PharmX Technologies Ltd ASX:PHX
40 GF Score
Price A$0.13
GF Value A$0.07
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is PharmX Technologies Moat Score?

PharmX Technologies has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

PharmX Technologies has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes PharmX Technologies might have No Moat - No discernible moat.

PharmX Technologies  (ASX:PHX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

PharmX Technologies Moat Score Related Terms

ASX:PHX
40GF Score
PharmX Technologies Ltd ASX:PHX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PharmX Technologies (ASX:PHX) Overvalued in 2026?

Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued. The current stock price of A$0.13 is trading 78.6% above its estimated GF Value™ of A$0.07. GuruFocus considers PharmX Technologies to be Significantly Overvalued.

Key valuation signals for ASX:PHX:

  • Moat Score: 0
  • GF Value™: A$0.07 vs. price of A$0.13 (78.6% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmX Technologies Business Description

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
40GF Score

Get the complete analysis for ASX:PHX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.13
Price
A$0.07
GF Value